Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.54 |
| ▸ | BRAF | P15056 | 5/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594996 | 0.83 | RAF1 (0.55) | RAF1BRAF | |
| SCHEMBL16095004 | 0.78 | RAF1 (0.56) | RAF1BRAF | |
| SCHEMBL14923457 | 0.76 | SCN9A (0.34) | RAF1 | |
| SCHEMBL16094074 | 0.75 | RAF1 (0.56) | RAF1BRAFPIK3CA | |
| SCHEMBL20264506 | 0.75 | RAF1 (0.54) | RAF1BRAF | |
| SCHEMBL17594680 | 0.74 | PIK3CA (0.43) | RAF1BRAFPIK3CA | |
| SCHEMBL20264813 | 0.73 | RAF1 (0.56) | RAF1BRAF | |
| SCHEMBL16094699 | 0.73 | RAF1 (0.58) | RAF1BRAF | |
| SCHEMBL16095043 | 0.73 | RAF1 (0.58) | RAF1BRAF | |
| SCHEMBL16094697 | 0.73 | RAF1 (0.58) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191478-B1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | NOVARTIS AG (CH) | 2019-01-01 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170917-A1 | COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PIK3CA 27/4885 |
| US-10167279-B2 | Compounds and compositions as RAF kinase inhibitors | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885PIK3CA 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.